We conclude that the observed gene upregulation could be explained by epigenetic changes and propose that AMER1, HSPA2, NCX1, and TNFRSF10C may contribute to the clinical effects of AZA in MDS. This evidence concerns the gene HSPA2 and myelodysplastic syndrome.